Theravance Biopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary

Theravance Biopharma

10/08/2026 22:00

Theravance Biopharma, Inc. TBPH.OQ reported quarterly breakeven results​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -54 cents.  The mean expectation of six analysts for the quarter was for earnings of 5 cents per share. Wall Street expected results to range from -2 cents to 18 cents per share.
Revenue fell 20.9% to $20.73 million from a year ago; analysts expected $21.60 million. 
Theravance Biopharma, Inc.'s reported EPS for the quarter was a loss of 11 cents​.
The company reported a quarterly loss of $5.9 million.
Theravance Biopharma, Inc. shares had fallen by 0.4% this quarter and lost 9.5% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 11.8% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is  "buy."
Wall Street's median 12-month price target for Theravance Biopharma, Inc. is $17.00, about 0.4% above its last closing price of $16.93
This summary was machine generated from LSEG data August 10 at 09:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
0.05
0.00
Missed
Mar. 31 2026 
-0.14
-0.03
Beat
Dec. 31 2025 
1.22
0.21
Missed
Sep. 30 2025 
-0.13
0.07
Beat